Comment

  • 25 May 2018

    Is artificial intelligence the future of drug discovery?

    The applications of artificial intelligence (AI) in healthcare are numerous, with the potential to transform key aspects of the industry, such as drug discovery. For many pharmaceutical companies, machine learning...

  • 24 May 2018

    Aimovig marks a new milestone for migraine

    Amgen’s Aimovig (erenumab) was recently approved by the FDA for the prevention of migraine; it is expected to launch in the US this week, securing the first-to-market position within a...

  • 24 May 2018

    China’s enrolment rate dips as phase rises

    On average, enrolment rates for clinical trials in China, which include both single-country and multinational trials, decrease as products move through the pipeline.

  • 22 May 2018

    The evolving story of IDO-1 inhibitors’ fall from grace

    Once touted as the next-biggest checkpoint inhibitor, indoleamine 2 3-dioxygenase 1 (IDO-1) inhibitors were praised for their extremely benign safety profile and were being studied in late-phase trials across all...

Close
Close
Close

Go Top